Premium
Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapy
Author(s) -
Zhu Xin Yan,
Liu Fei
Publication year - 2017
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12466
Subject(s) - medicine , helicobacter pylori , probiotic , adverse effect , adjuvant , asymptomatic , antibiotics , gastroenterology , immunology , microbiology and biotechnology , bacteria , biology , genetics
Over 80% of individuals infected with Helicobacter pylori ( H. pylori ) are asymptomatic. Increased resistance to antibiotics and decreased compliance to the therapeutic regimens have led to the failure of eradication therapy. Probiotics, with direct and indirect inhibitory effects on H. pylori in both animal models and clinical trials, have recently been used as a supplementary treatment in H. pylori eradication therapy. Probiotics have been considered useful because of the improvements in H. pylori eradication rates and therapy‐related side effects although treatment outcomes using probiotics are controversial due to the heterogeneity of species, strains, doses and therapeutic duration of probiotics. Thus, despite the positive role of probiotics, several factors need to be further considered during their applications. Moreover, adverse events of probiotic use need to be noted. Further investigations into the safety of adjuvant probiotics to H. pylori eradication therapy are required.